Search In this Thesis
   Search In this Thesis  
العنوان
Formulation and Evaluation of Novel Non- Invasive Drug Delivery System for Citicoline Sodium Drug /
المؤلف
Abou Elhassan, Kariman Musalim.
هيئة الاعداد
باحث / كريمان مسلم ابوالحسن عبدالرحيم
مشرف / حاتم عبدالمنصف سرحان
مشرف / أمل كمال حسين
مشرف / أشرف محمد ابوالوفا
مشرف / محمد أحمد صفوت
الموضوع
Alzheimer’s disease.
تاريخ النشر
2023.
عدد الصفحات
214 p. :
اللغة
الإنجليزية
الدرجة
الدكتوراه
التخصص
الصيدلة ، علم السموم والصيدلانيات (المتنوعة)
تاريخ الإجازة
1/2/2023
مكان الإجازة
جامعة المنيا - كلية الصيدلة - صيدلانيات
الفهرس
Only 14 pages are availabe for public view

from 262

from 262

Abstract

Context: Alzheimer’s disease (AD) is one of the furthermost advanced neurodegenerative disorders resulting in cognitive and behavioral impairment. Citicoline Sodium (CIT) boosts the brain’s secretion of acetylcholine, which aids in membrane regeneration and repair. However, it suffers from poor blood-brain barrier (BBB) permeation results in lower levels of CIT in the brain.
Purpose: This study targeted to encapsulate CIT into novel nano-platform Transbilosomes decorated with Hyaluronic acid CIT-HA*TBLs to achieve enhanced drug delivery from the nose to the Brain.
Methods: A method of thin-film hydration was utilized to prepare different formulae of CIT-TBLs using the Box-Behnken design. The optimized formula was then hyuloranated via integration of HA to form the CIT-HA*TBLs formula. Furthermore, AD induction was performed by Aluminum chloride (Alcl3), animals were allocated, and brain hippocampus tissue was isolated for ELISA and qRT-PCR analysis of Malondialdehyde (MDA), Nuclear Factor Kappa B (NF-kB), and microRNA-137 (miR-137) coupled with immunohistochemical amyloid-beta (Aβ1–42) expression and histopathological finding.
Results: The hyuloranated CIT-HA*TBLs formula, which contained the following ingredients: PL (300 mg), Sp 60 (43.97 mg), and SDC (20 mg).They produced spherical droplets at the nanoscale (178.94 ±12.4 nm), had a high entrapment efficiency with 74.92± 5.54 percent, had a sustained release profile of CIT with 81.27 ±3.8 percent release, and had ex-vivo permeation of CIT with 512.43±19.58 μg/cm2.
In-vivo tests showed that CIT-HA*TBL Thermogel dramatically reduces the hippocampus expression of miR-137 and (Aβ1–42) expression, boosting cholinergic neurotransmission and decreasing MDA and NF-kB production. Furthermore, CIT-HA*TBLs Thermogel mitigate histopathological damage in compared to the other groups
Conclusion: Succinctly, the innovative loading of CIT-HA* TBLs Thermogel is a prospectively invaluable intranasal drug delivery system that can raise the efficacy of CIT in Alzheimer’s management.